File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Modified tricalcium silicate cement formulations with added zirconium oxide

TitleModified tricalcium silicate cement formulations with added zirconium oxide
Authors
KeywordsCa release
Component distribution
Cytotoxicity
Mini-fracture toughness
Tricalcium silicate
Zirconium oxide
Issue Date2017
Citation
Clinical Oral Investigations, 2017, v. 21, n. 3, p. 895-905 How to Cite?
AbstractObjectives: This study aims to investigate the effect of modifying tricalcium silicate (TCS) cements on three key properties by adding ZrO2. Materials and methods: TCS powders were prepared by adding ZrO2 at six different concentrations. The powders were mixed with 1 M CaCl2 solution at a 3:1 weight ratio. Biodentine (contains 5 wt.% ZrO2) served as control. To evaluate the potential effect on mechanical properties, the mini-fracture toughness (mini-FT) was measured. Regarding bioactivity, Ca release was assessed using ICP-AES. The component distribution within the cement matrix was evaluated by Feg-SEM/EPMA. Cytotoxicity was assessed using an XTT assay. Results: Adding ZrO2 to TCS did not alter the mini-FT (p = 0.52), which remained in range of that of Biodentine (p = 0.31). Ca release from TSC cements was slightly lower than that from Biodentine at 1 day (p > 0.05). After 1 week, Ca release from TCS 30 and TCS 50 increased to a level that was significantly higher than that from Biodentine (p < 0.05). After 1 month, Ca release all decreased (p < 0.05), yet TCS 0 and TCS 50 released comparable amounts of Ca as at 1 day (p > 0.05). EPMA revealed a more even distribution of ZrO2 within the TCS cements. Particles with an un-reacted core were surrounded by a hydration zone. The 24-, 48-, and 72-h extracts of TCS 50 were the least cytotoxic. Conclusions: ZrO2 can be added to TCS without affecting the mini-FT; Ca release was reduced initially, to reach a prolonged release thereafter; adding ZrO2 made TCS cements more biocompatible. Clinical relevance: TCS 50 is a promising cement formulation to serve as a biocompatible hydraulic calcium silicate cement.
Persistent Identifierhttp://hdl.handle.net/10722/327744
ISSN
2023 Impact Factor: 3.1
2023 SCImago Journal Rankings: 0.942
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLi, Xin-
dc.contributor.authorYoshihara, Kumiko-
dc.contributor.authorDe Munck, Jan-
dc.contributor.authorCokic, Stevan-
dc.contributor.authorPongprueksa, Pong-
dc.contributor.authorPutzeys, Eveline-
dc.contributor.authorPedano, Mariano-
dc.contributor.authorChen, Zhi-
dc.contributor.authorVan Landuyt, Kirsten-
dc.contributor.authorVan Meerbeek, Bart-
dc.date.accessioned2023-05-08T02:26:31Z-
dc.date.available2023-05-08T02:26:31Z-
dc.date.issued2017-
dc.identifier.citationClinical Oral Investigations, 2017, v. 21, n. 3, p. 895-905-
dc.identifier.issn1432-6981-
dc.identifier.urihttp://hdl.handle.net/10722/327744-
dc.description.abstractObjectives: This study aims to investigate the effect of modifying tricalcium silicate (TCS) cements on three key properties by adding ZrO2. Materials and methods: TCS powders were prepared by adding ZrO2 at six different concentrations. The powders were mixed with 1 M CaCl2 solution at a 3:1 weight ratio. Biodentine (contains 5 wt.% ZrO2) served as control. To evaluate the potential effect on mechanical properties, the mini-fracture toughness (mini-FT) was measured. Regarding bioactivity, Ca release was assessed using ICP-AES. The component distribution within the cement matrix was evaluated by Feg-SEM/EPMA. Cytotoxicity was assessed using an XTT assay. Results: Adding ZrO2 to TCS did not alter the mini-FT (p = 0.52), which remained in range of that of Biodentine (p = 0.31). Ca release from TSC cements was slightly lower than that from Biodentine at 1 day (p > 0.05). After 1 week, Ca release from TCS 30 and TCS 50 increased to a level that was significantly higher than that from Biodentine (p < 0.05). After 1 month, Ca release all decreased (p < 0.05), yet TCS 0 and TCS 50 released comparable amounts of Ca as at 1 day (p > 0.05). EPMA revealed a more even distribution of ZrO2 within the TCS cements. Particles with an un-reacted core were surrounded by a hydration zone. The 24-, 48-, and 72-h extracts of TCS 50 were the least cytotoxic. Conclusions: ZrO2 can be added to TCS without affecting the mini-FT; Ca release was reduced initially, to reach a prolonged release thereafter; adding ZrO2 made TCS cements more biocompatible. Clinical relevance: TCS 50 is a promising cement formulation to serve as a biocompatible hydraulic calcium silicate cement.-
dc.languageeng-
dc.relation.ispartofClinical Oral Investigations-
dc.subjectCa release-
dc.subjectComponent distribution-
dc.subjectCytotoxicity-
dc.subjectMini-fracture toughness-
dc.subjectTricalcium silicate-
dc.subjectZirconium oxide-
dc.titleModified tricalcium silicate cement formulations with added zirconium oxide-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00784-016-1843-y-
dc.identifier.pmid27153848-
dc.identifier.scopuseid_2-s2.0-84966365373-
dc.identifier.volume21-
dc.identifier.issue3-
dc.identifier.spage895-
dc.identifier.epage905-
dc.identifier.eissn1436-3771-
dc.identifier.isiWOS:000398710700021-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats